Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Non-small cell lung cancer sunitinib erlotinib Phase 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 162
Healthy volunteers: no

Brief summary:
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: erlotinib intervention 2: sunitinib intervention 3: erlotinib intervention 4: placebo
Intervention descriptions: intervention 1: erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity intervention 2: Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity intervention 3: erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity intervention 4: Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity

Protocol document: